Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
River BioMedics is a biotech company that aims to develop human 3D in vitro 3D human heart tissue for pre-clinical drug testing. Currently pharmaceutical companies spend a billion dollar figure on the development of a new drug entity, with a 90% chance of it failing to reach the market. The most common reason for failure during this developmental stage is drug induced cardiac toxicity. To solve this issue we develop 3D cardiac tissues, resembling the working human heart, for advanced drug discovery and toxicity screening using a multidisciplinary human stem cell-based approach.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
CatalYm GmbH, founded in 2016 and based in Munich, Germany, specializes in the development of immuno-oncology therapeutics. The company focuses on creating antibodies that target a placental factor known to be overexpressed in various tumor types. Through its innovative approach, CatalYm aims to enhance cancer treatment options and improve patient outcomes in the field of oncology.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.
Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Azafaros B.V. is a Netherlands-based company focused on developing therapeutic agents for the treatment of rare metabolic disorders, specifically lysosomal storage disorders (LSDs). The company specializes in the oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the metabolism of glycosphingolipids and are designed to have a dual mode of action that can potentially improve patient outcomes. Through its research and development efforts, Azafaros seeks to provide effective treatments that can significantly enhance the lives of those affected by these severe inherited diseases.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.
Azafaros B.V. is a Netherlands-based company focused on developing therapeutic agents for the treatment of rare metabolic disorders, specifically lysosomal storage disorders (LSDs). The company specializes in the oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the metabolism of glycosphingolipids and are designed to have a dual mode of action that can potentially improve patient outcomes. Through its research and development efforts, Azafaros seeks to provide effective treatments that can significantly enhance the lives of those affected by these severe inherited diseases.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target ROR?t for the treatment of psoriasis and other autoimmune disorders. Escalier's lead topical and oral drug candidates are currently in late stage preclinical studies. Escalier is registered in The Netherlands with offices in Nijmegen, The Netherlands and Encinitas, California.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Mellon Medical B.V., established in 2013 and headquartered in Nijmegen, the Netherlands, specializes in the development and marketing of innovative suturing tools designed for surgical applications. The company focuses on creating instruments that enable surgeons to perform single-handed stitching, thereby enhancing the efficiency and effectiveness of suturing tubular and layered structures during medical procedures. By providing advanced suturing solutions, Mellon Medical aims to improve patient outcomes and support medical specialists in delivering high-quality healthcare.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.
Cristal Therapeutics BV operates as a clinical stage pharmaceutical company. It develops nanomedicines based on its proprietary CriPec and CriPec ATN platform to treat diseases which include cancer. The company develops technology to transform drugs into nanoparticles. It also provides programs to develop nanomedicines for various therapeutic areas. The company was founded in 2011 and is based in Maastricht, the Netherlands.
Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.
Cristal Therapeutics BV operates as a clinical stage pharmaceutical company. It develops nanomedicines based on its proprietary CriPec and CriPec ATN platform to treat diseases which include cancer. The company develops technology to transform drugs into nanoparticles. It also provides programs to develop nanomedicines for various therapeutic areas. The company was founded in 2011 and is based in Maastricht, the Netherlands.
Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.
Synaffix BV is a biotechnology company based in Oss, the Netherlands, focused on developing advanced antibody-drug conjugate (ADC) technology platforms for oncology. Established in 2010, the company offers proprietary solutions such as GlycoConnect, which enables site-specific and stable conjugation of anti-cancer agents by modifying glycan anchor points on antibodies. Additionally, Synaffix provides HydraSpace, a linker technology designed to enhance payload solubility and reduce aggregation in ADCs, alongside a metal-free click chemistry applicable across various sectors, including pharmaceuticals and academia. As a clinical-stage enterprise, Synaffix employs a technology out-licensing business model and engages in research collaborations with other organizations to facilitate the development of competitive ADC products. Its patent portfolio extends protection for resulting products through at least 2035, bolstering its position in the biotechnology landscape.
Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.
Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.
Dezima Pharma B.V., founded in 2012 and based in Naarden, the Netherlands, focuses on developing protein-based compounds for the treatment of cardiovascular diseases associated with dyslipidemia. The company specializes in creating novel drugs, including a cholesteryl ester transfer protein inhibitor, aimed at lowering low-density lipoprotein cholesterol levels. By addressing these lipid imbalances, Dezima Pharma provides clinicians with pharmacological therapies that can effectively treat patients suffering from dyslipidemic-related cardiovascular conditions.
Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company.
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Medisse is a Dutch company, founded in 2006, that develops, produces and markets resorbable soft tissue implants, based on bio-resorbable PTMC polymers. Medisse does yet not have commercial products but is working on the testing of its first product before market introduction. Medisse's first product will be an anti-adhesion barrier.
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Private Equity Round in 2009
FlexGen B.V., based in Leiden, the Netherlands, is a biotechnology company specializing in the development of technologies for synthesizing microarrays. Founded in 2004 as a spin-off from Leiden University Medical Centre and Dutch Space, FlexGen utilizes proprietary laser-based methods for in-situ synthesis of oligonucleotides and other biomolecules. The company offers the FlexArrayer, a bench-top instrument designed for in-house custom microarray synthesis, as well as various enrichment kits, including those for target enrichment and whole exome enrichment. FlexGen is dedicated to serving the genetic research market and is recognized for its innovative applications in microarray and oligopool synthesis.
Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.